TY - JOUR
KW - Buprenorphine, Naloxone Drug Combination
KW - Drug Combinations
KW - Humans
KW - Narcotic Antagonists
KW - Opioid-Related Disorders/drug therapy
KW - Substance Withdrawal Syndrome/etiology
AU - Eric Urnoski
A1 - 
AB - Combination buprenorphine-naloxone is a cornerstone of outpatient treatment for substance use disorder, and is more widely accessible in primary care. Because oral buprenorphine has been diverted and abused for its euphoric properties, a combination formulation was developed and will trigger withdrawal symptoms if injected IV.
AD - Eric Urnoski is a clinical pharmacist in critical care at Crozer-Chester Medical Center in Upland, Pa. The author has disclosed no potential conflicts of interest, financial or otherwise.
BT - JAAPA : official journal of the American Academy of Physician Assistants
C5 - Opioids & Substance Use
CP - 11
CY - United States
DO - 10.1097/01.JAA.0000525919.14882.ed
IS - 11
JF - JAAPA : official journal of the American Academy of Physician Assistants
LA - eng
M1 - Journal Article
N2 - Combination buprenorphine-naloxone is a cornerstone of outpatient treatment for substance use disorder, and is more widely accessible in primary care. Because oral buprenorphine has been diverted and abused for its euphoric properties, a combination formulation was developed and will trigger withdrawal symptoms if injected IV.
PP - United States
PY - 2017
SN - 1547-1896; 0893-7400
SP - 44
EP - 45
EP - 
T1 - Why is buprenorphine coformulated with naloxone?
T2 - JAAPA : official journal of the American Academy of Physician Assistants
TI - Why is buprenorphine coformulated with naloxone?
U1 - Opioids & Substance Use
U2 - 29064938
U3 - 10.1097/01.JAA.0000525919.14882.ed
VL - 30
VO - 1547-1896; 0893-7400
Y1 - 2017
Y2 - Nov
ER -